Synonyms: ASP 3026 | ASP3026
Compound class:
Synthetic organic
Comment: ASP-3026 is a second generation ALK inhibitor designed to target ALK rearrangements which are the oncogenic drivers of some non-small cell lung cancers (NSCLCs) and T-cell lymphomas known as ALK- expressing anaplastic large-cell lymphoma (ALK+ALCL) .
|
|
No information available. |
Summary of Clinical Use |
ASP-3026 is currently being assessed in clinical trials. Click here to view the list of ASP-3026 trials currently registered with ClinicalTrials.gov. |
Mechanism Of Action and Pharmacodynamic Effects |
ASP3026 inhibits ALK activity in an ATP-competitive manner, ie it acts at the enzyme's ATP binding [2]. |